Paola A. Ascierto, MD | Authors


Evaluating Therapy With Encorafenib, Binimetinib, and Ribociclib in Melanoma

June 06, 2017

Paola A. Ascierto, MD, medical oncologist, director of Melanoma Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori “Fondazione G. Pascal,” discusses results of a phase Ib/II dose-escalation study evaluating triple combination therapy with encorafenib, binimetiinib, and ribociclib (Kisquali) in patients with BRAF V600 solid tumors and melanoma.